ScholarIQanswers from OpenAlex

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study

PaperCitations, authors & open-access status

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study have?

ScholarIQcitation count

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study has 45 citations in the OpenAlex counts ScholarIQ stores.

When was Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study published?

ScholarIQyear

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study has 2013 year in the ScholarIQ index.

What is the open-access status of Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study?

ScholarIQoa status

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study has gold oa status in the ScholarIQ index.

What is the DOI of Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study?

ScholarIQdoi

The DOI for Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study is on the source record.

What is the PMID of Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study?

ScholarIQpmid

The PMID for Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study is on the source record.

What is the OpenAlex record for Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study?

ScholarIQopenalex

The OpenAlex for Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial